Why the study?
This pilot study aimed to assess the potential benefits of cardiac contractility modulation (CCM) in patients with heart failure with preserved ejection fraction (HFpEF).
Does cardiac contractility modulation therapy improve health status in patients with heart failure with preserved ejection fraction?
Population
47 patients with HFpEF and NYHA class II or III
Comparison
CCM therapy device implantation (single-arm)
Design
Prospective, multicentre, single-arm pilot study
Follow-up
24 weeks
Authors
Loading...
May support CCM investigation in HFpEF; leaves open efficacy pending randomized trials.
Does cardiac contractility modulation therapy improve health status in patients with heart failure with preserved ejection fraction?
Cardiac contractility modulation therapy significantly improved health status (KCCQ score) in patients with HFpEF over 24 weeks with a favorable safety profile.
Linde et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: